Mannkind Corp (MNKD) 6.81 $MNKD
12.2% Return Seen to Date on SmarTrend MannKind Call (MNKD)
Comtex SmarTrend(R) - Thu Sep 11, 10:28AM CDT
SmarTrend identified a Downtrend for MannKind (NASDAQ:MNKD) on August 12th, 2014 at $7.76. In approximately 1 month, MannKind has returned 12.19% as of today's recent price of $6.81.
3 Reasons MannKind Corporation's Stock Could Fall
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 09, 9:42AM CDT
In the short and medium terms, MannKind is dependent on a decent launch of the company's inhaled insulin drug/device Afrezza; if the launch fails to deliver, the share price is sure to sink. Only time will tell whether Afrezza will succeed or...
Why MannKind Corporation Stock Skyrocketed 38% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 7:23AM CDT
The SPDR S&P Biotech ETF has had a great year, advancing 22% since the year began. MannKind , however, has one-upped the broad-based biotech index with a 38% year-to-date gain of its own. MNKD data by YCharts What's caused...
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
PR Newswire - Wed Sep 03, 8:05AM CDT
The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished the session 0.05% lower at 2,002.28. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 737.75, up 0.02%, with the index gaining 6.88% in the previous three months. Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), Orexigen Therapeutics Inc. (NASDAQ: OREX), and IsoRay Inc. (NYSE MKT: ISR). Free research on these five companies can be accessed at:
MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
GlobeNewswire - Tue Sep 02, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 12:55 PM (ET) at the Grand Hyatt Hotel in New York City.
Critical Alerts For MannKind, Best Buy, Splunk, Rite Aid and Allscripts Released By InvestorsObserver
PR Newswire - Thu Aug 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, BBY, SPLK, RAD and MDRX.
After Yesterday's Rally of 1.70% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 27, 4:23PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $7.43 to a high of $7.64. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $7.40 on volume of 9.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
How Will MannKind (MNKD) Stock Respond to This Coverage Initiation?
at The Street - Wed Aug 27, 7:02AM CDT
MannKind (MNKD) had coverage initiated with a 'buy' rating and $10 price target at Jefferies (JEF)..
MNKD, DEPO, RWR, NTES, TTM, PAY Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Aug 18, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mannkind Corp (NASDAQ:MNKD), Depomed Inc (NASDAQ
EPO), Dj Wilshire Reit Etf (NYSE:RWR), NetEase.com Inc (NASDAQ:NTES), Tata Motors Ltd (NYSE:TTM), VeriFone Systems Inc (NYSE
AY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Ebola Vaccine and Inhaled Insulin Incoming
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Aug 16, 5:01AM CDT
In this healthcare-focused of episode of Where The Money Is, analysts David Williamson and Michael Douglass tackle the weeks biggest stories in pharma and biotech, and how the industry is attempting to combat the Ebola Outbreak. MannKind's big news...
MannKind Falls 2.70% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Aug 15, 4:32PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.66 to a high of $7.11. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $7.00 on volume of 16.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna
PR Newswire - Thu Aug 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), MannKind Corp. (NASDAQ: MNKD), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline PLC (NYSE: GSK) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5727-100free.
5 Things MannKind Corp.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 13, 5:30PM CDT
MannKind recently signed a marketing partnership with Sanofi and later in the day held a second conference call to discuss its second-quarter earnings. Here are five quotes from MannKind's management with details on the future of the company and...
Blame MannKind's Fall on its Bloated Balance Sheet
at The Street - Wed Aug 13, 11:04AM CDT
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
Uptrend Call Working As MannKind Stock Rises 0.6% (MNKD)
Comtex SmarTrend(R) - Tue Aug 12, 11:11AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 0.60% as of today's recent price of $7.50.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
eResearch Highlights NASDAQ Volume Leaders for Monday, August 11
ACCESSWIRE - Tue Aug 12, 9:02AM CDT
TORONTO, ON / ACCESSWIRE / August 12, 2014 / eResearch Corporation collaborates with theUpTrend.com in providing technical charts and opinions on the previous day's largest share volume leaders for each of the three major North American stock exchanges (on a rotating daily basis).
Critical Alerts For MannKind, Kinder Morgan, Kohls, Maxim Integrated Products and United Technologies. Released By InvestorsObserver
PR Newswire - Tue Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, KMI, KSS, MXIM and UTX.
MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 12, 6:00AM CDT
After years of discussions, MannKind finally has a partner for its inhaled insulin Afrezza. And a pretty good one at that. Source: MannKind The biotech announced a deal with diabetes expert Sanofi yesterday. There are two ways of...
MannKind Enters into a Global Deal with Sanofi for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 4:20PM CDT
MannKind (MNKD) has a inked a deal with Sanofi (SNY) on Afrezza.
12.2% Return Seen to Date on SmarTrend MannKind Call (MNKD)
Comtex SmarTrend(R) - Thu Sep 11, 10:28AM CDT
SmarTrend identified a Downtrend for MannKind (NASDAQ:MNKD) on August 12th, 2014 at $7.76. In approximately 1 month, MannKind has returned 12.19% as of today's recent price of $6.81.
3 Reasons MannKind Corporation's Stock Could Fall
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 09, 9:42AM CDT
In the short and medium terms, MannKind is dependent on a decent launch of the company's inhaled insulin drug/device Afrezza; if the launch fails to deliver, the share price is sure to sink. Only time will tell whether Afrezza will succeed or...
Why MannKind Corporation Stock Skyrocketed 38% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 7:23AM CDT
The SPDR S&P Biotech ETF has had a great year, advancing 22% since the year began. MannKind , however, has one-upped the broad-based biotech index with a 38% year-to-date gain of its own. MNKD data by YCharts What's caused...
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
PR Newswire - Wed Sep 03, 8:05AM CDT
The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished the session 0.05% lower at 2,002.28. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 737.75, up 0.02%, with the index gaining 6.88% in the previous three months. Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), Orexigen Therapeutics Inc. (NASDAQ: OREX), and IsoRay Inc. (NYSE MKT: ISR). Free research on these five companies can be accessed at:
MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
GlobeNewswire - Tue Sep 02, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 12:55 PM (ET) at the Grand Hyatt Hotel in New York City.
Critical Alerts For MannKind, Best Buy, Splunk, Rite Aid and Allscripts Released By InvestorsObserver
PR Newswire - Thu Aug 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, BBY, SPLK, RAD and MDRX.
After Yesterday's Rally of 1.70% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 27, 4:23PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $7.43 to a high of $7.64. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $7.40 on volume of 9.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
How Will MannKind (MNKD) Stock Respond to This Coverage Initiation?
at The Street - Wed Aug 27, 7:02AM CDT
MannKind (MNKD) had coverage initiated with a 'buy' rating and $10 price target at Jefferies (JEF)..
MNKD, DEPO, RWR, NTES, TTM, PAY Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Aug 18, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mannkind Corp (NASDAQ:MNKD), Depomed Inc (NASDAQ
EPO), Dj Wilshire Reit Etf (NYSE:RWR), NetEase.com Inc (NASDAQ:NTES), Tata Motors Ltd (NYSE:TTM), VeriFone Systems Inc (NYSE AY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: Ebola Vaccine and Inhaled Insulin Incoming
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Aug 16, 5:01AM CDT
In this healthcare-focused of episode of Where The Money Is, analysts David Williamson and Michael Douglass tackle the weeks biggest stories in pharma and biotech, and how the industry is attempting to combat the Ebola Outbreak. MannKind's big news...
MannKind Falls 2.70% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Aug 15, 4:32PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.66 to a high of $7.11. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $7.00 on volume of 16.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna
PR Newswire - Thu Aug 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), MannKind Corp. (NASDAQ: MNKD), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline PLC (NYSE: GSK) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5727-100free.
5 Things MannKind Corp.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 13, 5:30PM CDT
MannKind recently signed a marketing partnership with Sanofi and later in the day held a second conference call to discuss its second-quarter earnings. Here are five quotes from MannKind's management with details on the future of the company and...
Blame MannKind's Fall on its Bloated Balance Sheet
at The Street - Wed Aug 13, 11:04AM CDT
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
Uptrend Call Working As MannKind Stock Rises 0.6% (MNKD)
Comtex SmarTrend(R) - Tue Aug 12, 11:11AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 0.60% as of today's recent price of $7.50.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
eResearch Highlights NASDAQ Volume Leaders for Monday, August 11
ACCESSWIRE - Tue Aug 12, 9:02AM CDT
TORONTO, ON / ACCESSWIRE / August 12, 2014 / eResearch Corporation collaborates with theUpTrend.com in providing technical charts and opinions on the previous day's largest share volume leaders for each of the three major North American stock exchanges (on a rotating daily basis).
Critical Alerts For MannKind, Kinder Morgan, Kohls, Maxim Integrated Products and United Technologies. Released By InvestorsObserver
PR Newswire - Tue Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, KMI, KSS, MXIM and UTX.
MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 12, 6:00AM CDT
After years of discussions, MannKind finally has a partner for its inhaled insulin Afrezza. And a pretty good one at that. Source: MannKind The biotech announced a deal with diabetes expert Sanofi yesterday. There are two ways of...
MannKind Enters into a Global Deal with Sanofi for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 4:20PM CDT
MannKind (MNKD) has a inked a deal with Sanofi (SNY) on Afrezza.
